Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03897361 · ClinicalTrials.gov registry record · Phase 1
Stem Cell Gene Therapy for Cystinosis
A Phase 1 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03897361 is a Phase 1 study that has completed, run by University of California, San Diego. The registered enrollment target is 6 participants.
The verdict
NCT03897361, a Phase 1 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study is a Phase 1/2 clinical trial that will assess the safety and efficacy of enriched gene-corrected hematopoietic stem cells isolated from patients affected with cystinosis. (Investigational Product: CTNS-RD-04 or CTNS-RD-04-LB, where the suffix "-LB" stands for LentiBOOST)
Interventions
- GENETIC CTNS-RD-04 or CTNS-RD-04-LB (where the suffix "-LB" stands for LentiBOOST)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-07-08 |
| Est. Completion | 2024-09-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03897361
The ClinicalTrials.gov registry entry for NCT03897361 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CTNS-RD-04 or CTNS-RD-04-LB (where the suffix "-LB" stands for LentiBOOST) is the first listed.
NCT03897361 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03897361 about?
NCT03897361 is a clinical study titled "Stem Cell Gene Therapy for Cystinosis". This study is a Phase 1/2 clinical trial that will assess the safety and efficacy of enriched gene-corrected hematopoietic stem cells isolated from patients affected with cystinosis. (Investigational Product: CTNS-RD-04 or CTNS-RD-04-LB, where the suffix "-LB" stands for LentiBOOST)
What is the current status of trial NCT03897361?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2019-07-08. Estimated completion is 2024-09-18.
What interventions are being tested in trial NCT03897361?
The interventions under investigation include: CTNS-RD-04 or CTNS-RD-04-LB (where the suffix "-LB" stands for LentiBOOST) (GENETIC).
Who is sponsoring clinical trial NCT03897361?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.